logo-loader
RNS
UDG Healthcare

JPMorgan Sec.Plc - UDG Healthcare Plc 38.5a

RNS Number : 1743I
JPMorgan Securities Plc
10 August 2021
 

Ap24

 

FORM 38.5(a)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

 

1.       KEY INFORMATION

 

Name of exempt principal trader

J.P. Morgan Securities Plc

Company dealt in

UDG Healthcare Plc

Class of relevant security to which the dealings being disclosed relate (Note 1)

€0.05 ordinary shares

Date of dealing

9 August 2021

 

2.        DEALINGS (Note 2)

 

(a)      Purchases and sales

 

Total number of relevant securities acquired

Highest price paid (Note 3)

Lowest price paid

(Note 3)

370,561(New Borrow)*

571,520

N/A

10.7800 GBP

N/A

10.7550 GBP

 

 

Total number of securities disposed

Highest price received (Note 3)

Lowest price received

(Note 3)

112,823

10.7800 GBP

10.7000 GBP

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 4)

Number of relevant securities

(Note 5)

Price per unit

(Note 3)

Equity Swap

Opening a Long Position

 

 

 

 

 

 

 

 

Opening a Short Position

 

 

 

 

 

 

502

2,745

860

25,559

7,468

23,981

1,179

16,782

 

1,774

333,333

19,717

474

2,443

13,700

354

10.7298 GBP

10.7622 GBP

10.7628 GBP

10.7684 GBP

10.7699 GBP

10.7700 GBP

10.7748 GBP

10.7794 GBP

 

10.7601 GBP

10.7630 GBP

10.7699 GBP

10.7701 GBP

10.7705 GBP

10.7751 GBP

10.7802 GBP

 

Ap25

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 3)

 

 

 

 

 

3.      OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 

voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

Date of disclosure

10 August 2021

Contact name

Alwyn Basch

Telephone number

020 7742 7407

Name of offeree/offeror with which connected

UDG Healthcare Plc

Nature of connection (Note 6)

Financial adviser to CD&R Fund XI

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEPMMMTMTJBBJB
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read